Icatibant Medical Valley

Icatibant, the active ingredient in Icatibant Medical Valley, is a Bradykinin B2 receptor antagonist presented as an injection for subcutaneous use. It is indicated for the treatment of acute attacks of hereditary angioedema in patients with a confirmed diagnosis, providing rapid reduction of swelling and associated discomfort.

GNH USA supplies Icatibant Medical Valley as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The product is manufactured in the European Union under strict quality standards and distributed through GNH USA's global network.

Icatibant is used to treat hereditary angioedema by blocking the bradykinin B2 receptor pathway.

- Acute attacks of hereditary angioedema (HAE) type I: provides rapid relief of swelling and associated pain. - Acute attacks of hereditary angioedema (HAE) type II: reduces edema and improves airway patency. - Hereditary angioedema with normal C1‑inhibitor: alleviates symptoms during acute episodes.

Icatibant may be associated with several adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Injection site pain: mild to moderate discomfort at the injection site. - Redness or erythema: localized skin reddening. - Swelling at injection site: transient edema. - Nausea or headache: occasional gastrointestinal or neurologic symptoms.

Serious or Rare Side Effects: - Anaphylactic reaction: severe allergic response requiring immediate medical attention. - Angioedema of the face or airway: potentially life‑threatening swelling. - Hypotension: sudden drop in blood pressure that may cause dizziness or fainting.

Before prescribing icatibant, clinicians should consider several precautionary measures to ensure safe use.

- Confirm diagnosis: verify hereditary angioedema type I, II, or normal C1‑inhibitor before use. - Assess hypersensitivity: avoid in patients with known allergy to icatibant or its excipients. - Cardiovascular monitoring: use cautiously in patients with unstable cardiovascular disease. - Concomitant ACE inhibitor use: evaluate risk of increased bradykinin‑mediated effects. - Pregnancy and lactation: limit use to situations where benefit outweighs potential risk. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Icatibant can interact with other medications that influence the bradykinin pathway or affect hemodynamic stability.

Major Interactions (Avoid): - ACE inhibitors: may increase bradykinin levels and reduce icatibant efficacy. - Neprilysin inhibitors (e.g., sacubitril): can elevate bradykinin and counteract therapeutic effect. - Other B2 receptor antagonists: concurrent use may lead to additive effects and unclear safety.

Moderate Interactions (Monitor Closely): - Estrogen‑containing contraceptives: may affect frequency of HAE attacks and require monitoring. - Subcutaneous biologics administered at the same site: risk of local irritation or altered absorption. - Antihypertensive agents: monitor blood pressure as icatibant may cause transient hypotension.